John Leaman

2021 - IMPEL PHARMACEUTICALS

In 2021, John Leaman earned a total compensation of $2.1M as Chief Financial & Business Officer at IMPEL PHARMACEUTICALS, a 283% increase compared to previous year.

Compensation breakdown

Bonus$300,000
Non-Equity Incentive Plan$230,000
Option Awards$529,300
Salary$434,365
Stock Awards$569,151
Total$2,062,816

Leaman received $569.2K in stock awards, accounting for 28% of the total pay in 2021.

Leaman also received $300K in bonus, $230K in non-equity incentive plan, $529.3K in option awards and $434.4K in salary.

Rankings

In 2021, John Leaman's compensation ranked 5,933rd out of 12,415 executives tracked by ExecPay. In other words, Leaman earned more than 52.2% of executives.

ClassificationRankingPercentile
All
5,933
out of 12,415
52nd
Division
Manufacturing
2,511
out of 5,505
54th
Major group
Chemicals And Allied Products
1,094
out of 2,375
54th
Industry group
Drugs
973
out of 2,096
54th
Industry
Pharmaceutical Preparations
702
out of 1,546
55th
Source: SEC filing on April 26, 2022.

Leaman's colleagues

We found two more compensation records of executives who worked with John Leaman at IMPEL PHARMACEUTICALS in 2021.

2021

Adrian Adams

IMPEL PHARMACEUTICALS

Chief Executive Officer

2021

Leonard Paolillo

IMPEL PHARMACEUTICALS

Chief Commercial Officer

News

You may also like